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Objective:  The  vasorelaxant  effect  of 2-arachidonoylglycerol  (2-AG)  has  been  well  characterised  in ani-
mals. 2-AG  is  present  in human  vascular  cells  and  is up-regulated  in  cardiovascular  pathophysiology.
However, the  acute  vascular  actions  of  2-AG  have  not  been  explored  in humans.
Approach:  Mesenteric  arteries  were  obtained  from  patients  receiving  colorectal  surgery  and  mounted
on a  myograph.  Arteries  were  contracted  and  2-AG  concentration–response  curves  were  carried  out.
Mechanisms  of  action  were  characterised  pharmacologically.  Post  hoc  analysis  was  carried  out  to assess
the  effects  of cardiovascular  disease/risk  factors  on  2-AG  responses.
Results:  2-AG  caused  vasorelaxation  of  human  mesenteric  arteries,  independent  of  cannabinoid  recep-
tor or  transient  receptor  potential  vanilloid-1  activation,  the  endothelium,  nitric  oxide  or metabolism
via  monoacyglycerol  lipase  or  fatty  acid amide  hydrolase.  2-AG-induced  vasorelaxation  was reduced
in  the  presence  of indomethacin  and  ﬂurbiprofen,  suggesting  a role  for cyclooxygenase  metabolism  2-
AG.  Responses  to 2-AG  were  also  reduced  in the  presence  of Cay10441,  L-161982  and  potentiated  in  the
presence  of  AH6809,  suggesting  that  metabolism  of 2-AG  produces  both  vasorelaxant  and  vasoconstrictor
prostanoids.  Finally,  2-AG-induced  vasorelaxation  was  dependent  on  potassium  efﬂux and  the  presence
of extracellular  calcium.
Conclusions:  We  have  shown  for the ﬁrst  time  that  2-AG causes  vasorelaxation  of  human  mesenteric
arteries.  Vasorelaxation  is  dependent  on COX  metabolism,  activation  of  prostanoid  receptors  (EP4 &  IP)
and ion channel  modulation.  2-AG responses  are  blunted  in  patients  with  cardiovascular  risk  factors.
© 2014  The Authors.  Published  by Elsevier  Ltd. Open access under CC BY license.. Introduction
The endocannabinoid 2-arachidonoylglycerol (2-AG), found in
uman patient plasma at low nanomolar concentrations [1], func-
ions in a paracrine manner [2]. Synthesis of 2-AG occurs on demand
hrough hydrolysis of a range of phospholipid precursors, and
egradation occurs through multiple pathways including monoa-
ylglycerol lipase (MAGL), fatty acid amide hydrolase (FAAH) and
yclooxygenase (COX) dependent pathways [3]. 2-AG binds to the
Abbreviations: 2-AG, 2-arachidonoylglcerol; AEA, anandamide; ANOVA, analysis
f  variance; CB1, cannabinoid receptor one; CB2, cannabinoid receptor two; COX-
,  cyclooxygenase one; COX-2, cyclooxygenase two; ECS, endocannabinoid system;
AAH, fatty acid amide hydrolase; KPSS, high potassium physiological saline solu-
ion; l-NAME, NG-nitro-l-arginine methyl ester; MAGL, monoacylglycerol lipase;
PAR, peroxisome proliferator activated receptor; PSS, physiological saline solution;
EM, standard error of mean; TRPV1, transient receptor potential vanilloid-1.
∗ Corresponding author. Tel.: +44 1332 724701.
E-mail addresses: mbzso@nottingham.ac.uk, christopher.stanley@pharm.ox.ac.uk
C.P. Stanley).
ttp://dx.doi.org/10.1016/j.phrs.2014.02.001
043-6618 © 2014 The Authors. Published by Elsevier Ltd. Open access under CC BY license.CB1 and CB2 receptors at high nanomolar and low micromolar
concentrations respectively [4], and causes slight calcium inﬂux
through TRPV1 channels [5].
In vivo, 2-AG administration induces hypotension through COX
metabolism in mice [6], and through the CB1 receptor in rats [7].
In vitro, 2-AG causes vasorelaxation of bovine coronary arteries that
is dependent on metabolism by MAGL, FAAH, COX  and cytochrome
P450 [8]. Conversely, in rat mesenteric arteries, metabolism of 2-
AG appears to limit vasorelaxation [9] and causes contraction of the
aorta [10]. In rabbit mesenteric arteries, 2-AG-induced vasorelax-
ation is unaffected by inhibition of COX and nitric oxide, blockage
of potassium channels or endothelium denudation, but is inhibited
by high concentrations of CB1 antagonist [11]. Variations between
these results may  be accredited to the different species used or dif-
ferent vascular beds studied [12]. To date, no studies have examined
the vascular responses of 2-AG in humans.Levels of 2-AG, and other components of the endocannabi-
noid system, have been shown to be altered in human vascular
disease and models of vascular disease including atherosclerosis
[13,14] and heart disease [15,16]. A full understanding as to the
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easons for these alterations in cardiovascular pathophysiology
s as yet unclear. However, there is evidence to suggest that in
ome forms of cardiovascular dysfunction, increased endocannabi-
oid activity may  be protective. Endocannabinoid stimulation of
annabinoid receptors causes greater vasorelaxation in hyperten-
ive rats compared to normotensive counterparts [17], decreases
ontractile sensitivity to the thromboxane mimetic U46619 in
at middle cerebral arteries [18], reduces myocardial infarct size
19,20], reduces atherosclerotic plaque size [21] and reduces car-
iac ischaemia/reperfusion injury [22].
Despite the fact that 2-AG and other components of the endo-
annabinoid system are present in the human cardiovascular
ystem [23–25,15] and that 2-AG causes release of nitric oxide from
uman endothelial cells in a CB1 dependant manner [26] the acute
ascular effects of 2-AG have not been studied in human arter-
es. Understanding the pharmacological effects of this endogenous
annabinoid in human vascular tissue may  aid in further under-
tanding of any potential role of 2-AG and the endocannabinoid
ystem in human cardiovascular pathologies. Therefore, the aim of
his study was to examine the acute vascular effects of the 2-AG and
haracterise the underlying pharmacology in human mesenteric
rteries.
. Methods
.1. General methods
The Derbyshire Research Ethics Committee and Derbyshire Hos-
itals Trust Research and Development granted ethical approval
or the use of mesenteric tissue from patients undergoing sur-
ical treatment of bowel carcinoma and inﬂammatory bowel
isorders (patient characteristics supplementary data Table 1).
xcised mesenteric tissue was placed in physiological saline
olution (PSS) (composition, mmol/L: Sodium chloride 119, potas-
ium chloride 4.7, calcium chloride 2.5, magnesium sulfate 1.17,
odium bicarbonate 25, potassium phosphate 1.18, EDTA 0.027,
lucose 5.5, dissolved in triple distilled water) and transported
ack to the lab. Arteries (668 ± 40 m S.E.M diameter, n = 162
rterial segments from 44 patients) were dissected from mesen-
eric tissue, cleaned of adherent adipose and connective tissue
nd cut into 2 mm segments. Artery segments were mounted
n ﬁne tungsten wires (40 m diameter) on a myograph (Dan-
sh Myo  Technology, Denmark) at 37 ◦C in PSS solution and
assed with 5% CO2 in O2. Tension was measured using isomet-
ic force displacement transducers and recorded using Chart 5
ro (ADInstruments, Oxfordshire, UK). Once mounted, arteries
ere normalised using normalisation software (ADInstruments,
xfordshire, UK), setting the arteries to an internal diameter
hat produced 90% of 13.3 kPa (0.9L100) [27], this gave an aver-
ge baseline of 4.2 ± 0.2 mN (n = 162 arterial segments from 44
atients). Artery segments were either used fresh (n = 24) or after
vernight storage in PSS at 4 ◦C (n = 20). Initial experiments revealed
vernight storage had no signiﬁcant effect on the contractile or
elaxation responses of mesenteric arteries (supplementary data
ig. 1A–D). Arteries were contracted using high potassium physi-
logical saline solution (124 nmol/L KPSS) (composition, mmol/L:
odium chloride 0, potassium chloride 124, calcium chloride 2.5,
agnesium sulfate 1.17, sodium bicarbonate 25, potassium phos-
hate 1.18, EDTA 0.027, glucose 5.5 all dissolved in triple distilled
ater) and 50 nmol/L U46619, and were relaxed using 10 mol/L
radykinin. An increase in tension of greater than 5 mN to both
PSS (20.3 ± 0.7 mN  increase in tone, n = 162 arterial segments
rom 44 patients) and U46619 (78 ± 2.1% second KPSS response,
 = 162 arterial segments from 44 patients), and a relaxation greater
han 70% to bradykinin (mean 88 ± 1.5% relaxation, n = 162 arterialogical Research 81 (2014) 74–82 75
segments from 44 patients) against U46619 pre-imposed tone
was used to validate smooth muscle and endothelium function
[28].
2.2. Experimental protocol
Viable arteries were contracted using combinations of U46619
(50–250 nmol/L: and endothelin-1 (1–3 nmol/L). Once a sta-
ble contraction greater than 5 mN (mean 16 ± 0.6 mN,  n = 162
arterial segments from 44 patients) was achieved, cumulative
concentration–response curves were constructed to 2-AG. 2-AG
was added in 5-min intervals with measurements taken, and
expressed as percentage relaxation of pre-imposed tone, in the ﬁnal
minute of each concentration addition. Responses were compared
to ethanol-treated vehicle controls carried out in adjacent arte-
rial segments from the same patient. In experiments to determine
the effects of 2-AG on baseline tone, arteries were not contracted
and a 2-AG concentration-response curve performed on arteries
at normalised baseline tone. Any response was then subtracted
off the pre-2-AG baseline and expressed as  alterations in tone,
this was  compared to vehicle treated control segments of adja-
cent arteries from the same patient. All arteries used in this study
were taken from the mesentery distal to the colon smooth muscle
wall. However, given that the operation type (right hemicolec-
tomy, left hemicolectomy, anterior resection/abdominoperineal
resection and total colectomy) may  inﬂuence vascular responses
based on different blood supply from differing feed vessels, 2-AG
concentration response curves were compared to reveal no signiﬁ-
cant difference in the 2-AG concentration response curve in arteries
obtained through different surgeries (supplementary data Fig. 1E).
In subsequent experiments to characterise the mechanisms that
underpin 2-AG-induced vasorelaxation, the patient’s samples were
randomly assigned to a range of intervention groups. The split of
patients between intervention groups is shown in supplementary
data Table 4, showing no distinct pattern that could potentially
inﬂuence results. In intervention studies, a length of arterial branch
was taken from the patient sample. This branch was then typically
cut into four 2 mm segments, one segment was  treated with 2-
AG alone (control), the remaining three segments were pre-treated
with a range of interventions (described below) and then treated
with 2-AG.
Potential cannabinoid receptor involvement in 2-AG-induced
vasorelaxation was assessed with the CB1 and cannabinoid recep-
tor 2 (CB2) receptor antagonists AM251 (100 nmol/L) and AM630
(100 nmol/L) both incubated for 10 min  prior to artery contraction
[29,30]. Desensitisation of the TRPV1 receptor was accomplished
via incubation (1 h) with the TRPV1 agonist, capsaicin (10 mol/L)
followed by 3 washouts in PSS [5]. In some experiments, the
endothelium was removed by gentle abrasion using a human hair
[30], removal of the endothelium was conﬁrmed by a less than 10%
vasorelaxation to 10 mol/L bradykinin. A role for the involvement
of nitric oxide was  investigated using NG-nitro-l-arginine methyl
ester (l-NAME, 300 mol/L) present throughout [30].
Metabolism of 2-AG into vasoactive compounds was  assessed
by 10 min  pre-contraction incubation with the MAGL inhibitor
JZL184 (1 mol/L) and the FAAH inhibitor URB597 (1 mol/L) [9].
The potential role of COX metabolism was assessed using the
non-selective COX inhibitor indomethacin (10 mol/L) [31], the
COX-1 favourable inhibitor ﬂurbiprofen (10 mol/L) or the COX-
2 inhibitor nimesulide (10 mol/L) [9] all present throughout. A
role for vasorelaxant prostanoid receptors was investigated using;
the DP1/EP2 receptor antagonist AH6809 (initially at a concentra-
tion of 10 mol/L, however this signiﬁcantly inhibited contractile
responses therefore a concentration of 1 mol/L was used, 30 min
incubation) [32], the EP4 receptor antagonist L-161982 (1 mol/L,
76 C.P. Stanley, S.E. O’Sullivan / Pharmacological Research 81 (2014) 74–82
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B).  2-AG effects on baseline tone compared to vehicle treated segments of mesente
Students paired t-test of area under curve *P < 0.05, ***P < 0.001).
0 min  prior to contraction) [33] or the IP receptor antagonist
ay10441 (100 nmol/L, 10 min  incubation) [34].
A potential role for potassium channel hyperpolarisation was
nvestigated by carrying out concentration–response curves to
-AG in arteries contracted using KPSS to inhibit potassium
fﬂux [35]. To investigate whether 2-AG causes vasorelaxation
n a calcium-dependant manner, arteries were contracted using
46619 in calcium-free PSS. To investigate the effects of 2-AG
n calcium inﬂux, concentration–response contractions to calcium
hloride were carried out in arteries that were incubated with
alcium-free PSS (10 min), calcium-free KPSS (10 min) and then 2-
G (10 min  with 10 or 100 mol/L) or vehicle control (1% ethanol)
35].
The effect of antagonists/inhibitor incubations on baseline tone
an be seen in supplementary data Table 3. It should be noted that
apsaicin pre-treatment signiﬁcantly lowered baseline tone and
ncubation with 10 mol/L AH6809 signiﬁcantly inhibited U46619
nd endothelin-1 contraction. All other techniques employed did
ot affect arterial contraction compared to arteries that had no prior
ncubation.
.3. Statistical analysisGraphs represent mean percentage relaxations, with error
ars representing the standard error of the mean (S.E.M.), and
 equalling the number of patients unless otherwise stated. Sig-
oidal concentration–responses curves with a standard hill slope compared to vehicle-treated segments of mesenteric artery from the same patient
ery from same patient (C). Data given as means with error bars representing S.E.M.
of 1 were ﬁtted to those data (Prism Version 5; GraphPad Soft-
ware, California, USA). In vasorelaxation studies comparisons were
made between intervention and control artery segments from the
same patient. Despite the clear alterations in 2-AG concentra-
tion response curves in the presence of a range of inhibitors and
antagonists, the effects on pEC50 and Rmax values were modest
(supplementary data Table 2). Therefore, data were also analysed
using paired Student t-tests of area under the curve (AUC) to detect
overall alterations in concentration response curves. The AUC  was
deﬁned as the area between the mean response value and the
baseline value of 0% relaxation (100% of contractile tone). In CaCl2
contraction studies, comparisons of AUC were made using one-way
analysis of variance (ANOVA) with Dunnetts post hoc analysis. Com-
parisons between responses to KPSS, U46619 and bradykinin in
fresh tissue and tissue that had been stored overnight (supplemen-
tary data Fig. 1) or between gender based responses to 10 mol/L
bradykinin (supplementary data Fig. 2C) were made using Student’s
unpaired t-test. Comparisons of 2-AG response curves based on
gender were made using Student’s unpaired t-test of area under the
curve (supplement data Fig. 2a). All correlations studies were made
using linear regression. Signiﬁcance was determined with P < 0.05.2.4. Drugs
All salts, L-NAME, indomethacin, bradykinin, endothelin-1, JZL
184, URB597 and AH6809 were supplied by Sigma Chemical Co.
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Fig. 2. 2-AG-induced vasorelaxation of human mesenteric arteries after 10 min
incubation with the CB1 antagonist AM251 (100 nmol/L) (A), CB2 antagonist AM630
(100 nmol/L) (B) and after 1 h desensitisation of the TRPV1 receptor using the TRPV1
agonist capsaicin (10 mol/L) (C). Data given as means with error bars representing
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AG pEC50 and/or Rmax values often varied between patients. Post
hoc analysis revealed that 2-AG pEC and/or R were reduced.E.M. Comparisons made between control and intervention segments of the same
rtery using Students paired t-test of area under curve.
UK). U46619, nimesulide, ﬂurbiprofen, AM251, AM630, capsaicin,
nd L-161,982 were purchased from Tocris (UK). 2-AG was  pur-
hased from Ascent Scientiﬁc (UK). CAY10441 was  purchased
rom Caymen Chemicals (Cambridge Bioscience, UK). l-NAME,
ndomethacin, nimesulide and ﬂurbiprofen were dissolved in PSS.
-AG, capsaicin, AH6809, CAY10441 and L-161,982 were dissolved
n ethanol at 10 mmol/L with further dilutions made in distilled
ater. AM251, AM630, JZL184 and URB597 were dissolved inogical Research 81 (2014) 74–82 77
DMSO at 10 mmol/L with further dilutions made in distilled water.
Bradykinin was  dissolved in distilled water at 10 mmol/L.
3. Results
3.1. General
Using wire myography, initial experiments revealed 2-AG
caused concentration-dependant vasorelaxation of pre-constricted
human mesenteric arteries with respective pEC50 and Rmax values
of 5.4 ± 0.2 and 42.4 ± 2.8 respectively (see Fig. 1A and B). 2-AG
also caused a modest reduction in baseline tone (Fig. 1C). Subse-
quent investigations using a range of inhibitors and antagonists
were then carried out to underpin the mechanisms of 2-AG-induced
vasorelaxation.
3.2. Potential receptor and endothelium roles in 2-AG induced
vasorelaxation
Antagonism of the CB1 (AM251, 100 nmol/L) or CB2 (AM630,
100 nmol/L) receptors (Fig. 2A and B), desensitisation of the TRPV1
receptor using capsaicin (10 mol/L) (Fig. 2C), removal of the
endothelium or incubation of endothelium intact arteries with l-
NAME had no effect on vasorelaxation to 2-AG in human mesenteric
arteries (Fig. 3A and B).
3.3. Potential roles for 2-AG metabolism in 2-AG induced
vasorelaxation
Incubation with the MAGL inhibitor JZL184 (1 mol/L) or
the FAAH inhibitor URB597 (1 mol/L) had no effect on 2-AG-
induced vasorelaxation (Fig. 3C and D). However, incubation
with the non-selective COX inhibitor indomethacin (10 mol/L)
signiﬁcantly reduced 2-AG-induced vasorelaxation (Fig. 4A). Fur-
thermore, the COX-1 inhibitor ﬂurbiprofen (10 mol/L), but not the
COX-2 inhibitor nimesulide (10 mol/L), inhibited 2-AG-induced
vasorelaxation (Fig. 4B and C). Antagonism of the prostanoid IP
(CAY10441, 100 nmol/L) and EP4 (L-161,982, 1 mol/L) receptors
signiﬁcantly reduced the vasorelaxant responses to 2-AG (Fig. 4D
and E). However, the prostanoid EP1, EP2, EP3, DP and TP receptor
antagonist (AH 6809, 1 mol/L) potentiated the response to 2-AG
(Fig. 4D).
3.4. Potential ion channel involvement in 2-AG induced
vasorelaxation
In KPSS contracted arteries, 2-AG-induced vasorelaxation was
inhibited (Fig. 5A). In arteries contracted with U46619 in calcium
free PSS, 2-AG-induced vasorelaxation was signiﬁcantly inhibited
(Fig. 5B). In arteries bathed in high potassium calcium free solu-
tion and incubated with 2-AG, the maximum contraction to calcium
chloride was  inhibited in arteries incubated with 100 mol/L, but
not 10 mol/L 2-AG (Fig. 5C).
3.5. The effect of patient co-morbidities on 2-AG-induced
vasorelaxation
It should be noted that in patient numbers used in this study
were too small to show conclusive data concerning the effects of
various patient pathophysiology’s on 2-AG responses. However, 2-50 max
in those with heart disease, type two diabetes, those taking NSAID,
statin and anti-diabetic medication (see supplementary data Table
5).
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Fig. 3. 2-AG-induced vasorelaxation of human mesenteric arteries after removal of
the  endothelium (A), in the presence of l-NAME (300 mol/L) (B), in the presence of
the MAGL inhibitor JZL184 (1 mol/L) (C) and the FAAH inhibitor URB597 (1 mol/L).
(D) Data given as means with error bars representing S.E.M. Comparisons made
between control and intervention segments of the same artery using Students paired
t-test of area under curve.ogical Research 81 (2014) 74–82
4. Discussion
There is growing interest in the role of 2-AG in cardiovascu-
lar disorders. This work is the ﬁrst to characterise 2-AG-induced
vasorelaxation in the human mesenteric artery, which is depend-
ent on COX-1 metabolism, activation of the prostanoid EP4 and IP
receptors, potassium hyperpolarisation and calcium channel mod-
ulation.
2-AG causes vasorelaxation in a variety vascular beds [6,11,8,9]
and circulating 2-AG levels are increased in a range of CVS disor-
ders [13–16]. However the direct effect of 2-AG on human arterial
tone is unknown. We  have shown that 2-AG relaxes human mesen-
teric arteries with a similar potency and efﬁcacy to that observed
in rat mesenteric arteries [9], but lower than that observed in rab-
bit mesenteric arteries [11]. The concentrations of 2-AG required
to elicit vasorelaxation are above the reported physiological and
pathophysiological plasma levels of 2-AG [1]. However, 2-AG is
an unstable compound [36] that is produced on demand to func-
tion in a paracrine fashion [2]. Therefore, it is unlikely that plasma
concentrations of 2-AG reﬂect cellular/local 2-AG concentrations.
Activation of CB1, CB2 or TRPV1 has been shown to partially
underpin the vasoactive effects of other cannabinoid ligands [37],
and 2-AG activation of the CB1 receptor causes vasorelaxation of
rat cerebral arteries and rabbit mesenteric arteries [11,38]. The
potential role of the CB2 and TRPV1 receptor in 2-AG induced
vasorelaxation was previously untested. In the present study, 2-
AG-induced vasorelaxation of the human mesenteric was not found
to be mediated by CB1, CB2 and TRPV1 receptors, although all are
present in human vascular smooth muscle cells [23,25,39] and
endothelial cells [40,25]. The nuclear peroxisome proliferator acti-
vated receptors (PPAR) were also considered as potential target
sites. Activation of the PPAR receptor has been shown to increase
cAMP [41], with both activation of PPAR and increased cAMP lead-
ing to improved endothelial function and enhanced vasorelaxation
in the aortae of diabetic mice [42]. Despite the ﬁndings that show
2-AG is a able to activate PPAR receptors in human Jurkat cells
[43] and that other endocannabinoids are able to cause vasorelax-
ation through PPAR receptors [44] it seems unlikely that 2-AG is
acting in through these pathways in the present study for several
reasons. Firstly, in the present study 2-AG concentration response
curves were completed in 45 min, however previous studies have
shown that endocannabinoid/PPAR mediated vasorelaxation is
time-dependant with only slight effects occurring between 30
and 45 min  [44]. Finally, cannabinoids have been shown to cause
vasorelaxation through PPAR in aortae but not mesenteric arter-
ies [45]. Vasorelaxation to 2-AG and other endocannabinoids in
animal models is endothelium-dependent [37,9]. However, we
found that 2-AG-induced vasorelaxation in human mesenteric
arteries is not inhibited by removal of the endothelium or inhi-
bition of endogenous nitric oxide production. Furthermore, the
maximal vasorelaxant response to 2-AG was not correlated with
the endothelium-dependent response to bradykinin in the same
patient. A lack of a role for the endothelium or nitric oxide
production in the vascular response to 2-AG in human mesenteric
arteries is in agreement with previous ﬁndings in rabbit mesenteric
arteries [11], but not in rat mesenteric arteries [9] or bovine coro-
nary arteries [8], possibly highlighting species differences in 2-AG
vascular responses.
2-AG can be hydrolysed by MAGL and FAAH [3]. Hydrolysis
of 2-AG, potentially through both these pathways has previously
been shown to cause vasorelaxation of bovine coronary arteries [8].
However, we  found that 2-AG-induced vasorelaxation in human
mesenteric arteries is not mediated by 2-AG hydrolysis through
MAGL or FAAH. COX-1 and -2 are expressed in human endothelium
and smooth muscle cells [46], and 2-AG serves as a substrate for
COX metabolism [47,48]. COX metabolism has been implicated in
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Fig. 4. 2-AG-induced vasorelaxation of human mesenteric arteries after addition of the non-selective COX inhibitor indomethacin (10 mol/L) (A), the COX-1 inhibitor
ﬂurbiprofen (10 mol/L) (B), the COX-2 inhibitor nimesulide (10 mol/L) (C), the prostanoid IP receptor antagonist CAY10441 (100 nmol/L) (D) the prostanoid EP antagonist
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n-161,982 (1 mmol/L) (E) and the prostanoid EP1, EP2, EP3, DP and TP receptor an
omparisons made between control and intervention segments of the same artery 
asorelaxation to 2-AG in the bovine coronary artery [8], but not rat
r rabbit mesenteric arteries [11,9]. We  found that 2-AG-induced
asorelaxation of the human mesenteric artery is inhibited by the
on-selective COX inhibitor indomethacin, the COX-1 favourable
nhibitor ﬂurbiprofen, but not the COX-2 inhibitor nimesulide. This
uggests that 2-AG induced vasorelaxation occurs through COX-1
ependent pathways. However, previous works have shown that
OX-1 metabolism of 2-AG is unlikely given that unlike COX-2,
OX-1 does not express the Arg-513 residue that is key in the bind-
ng of 2-AG to COX-2. To inhibit COX-2, nimesulide was  used in this
tudy. Although interactions have been shown between nimesulide
nd Arg-513, Arg-513 is not reported as the main binding site of
imesulide to COX-2 [49–51]. Therefore, it is possible that 2-AG4
ist (AH 6809, 1 mol/L). Data given as means with error bars representing S.E.M.
Students paired t-test of area under curve. **P  < 0.01, ***P < 0.001.
may  have still had the ability to bind too, and be metabolised by
COX-2 in the presence of nimesulide. However, the role for the
metabolism of COX-1 in the vasorelaxant effects of 2-AG has previ-
ously been shown in the rat mesenteric artery where 2-AG-induced
vasorelaxation was limited by COX-1 metabolism [9]. Taken with
the present study, this would suggest a need for further research
into the metabolism of 2-AG by both COX isoforms in the vascula-
ture.
COX metabolism of 2-AG produces a range of novel prostanoid
glycerol esters [52] that undergo hydrolysis to prostaglandins [53].
We therefore investigated potential roles for the DP1, EP2, EP4 and
IP prostanoid receptors, which are all reported to cause vasore-
laxation [54,55], and found that 2-AG-induced vasorelaxation is
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Fig. 5. 2-AG-induced vasorelaxation of human mesenteric arteries in arteries con-
tracted with KPSS (124 mmol/L) (A) and U46619 in Ca2+−free PSS buffer (B). The
effects of 10 min incubation with 2-AG (10 and 100 mol/L) and vehicle control
(0.1% EtOH) on CaCl2 contraction in Ca2+ free KPSS (124 mmol/L). Data given as
means with error bars representing S.E.M. Comparisons made between control and
intervention segments of the same artery using Students paired t-test of area under
c
t
d
S
v
p
r
P
eurve (A and B) and one way  ANOVA of area under the curve with Dunnets post hoc
est (C). *P < 0.05, **P  < 0.01, ***P < 0.001.
ependent on activation of the prostanoid EP4 and IP receptors.
imilarly, in the rat aorta, the endocannabinoid anandamide causes
asorelaxation partly by activation of EP4 receptors [56]. Since,
rostaglandin glycerol esters are unable to activate prostanoid
eceptors [52], it is likely that COX metabolism of 2-AG results in
GE2 and PGI2 formation, either directly or via prostaglandin glyc-
rol ester production and subsequent hydrolysis to prostanoids.ogical Research 81 (2014) 74–82
The ﬁnding that AH6809 potentiated 2-AG induced vasorelaxation
might be explained due to AH6809 having afﬁnity for prostanoid
receptors that bring about vasoconstriction [57]. Metabolism of
2-AG through COX-1 may  result in formation of both contractile
and relaxant prostanoids, the balance of which is predominantly
vasorelaxant.
When arteries were contracted using high potassium PSS to
inhibit potassium efﬂux, 2-AG-induced vasorelaxation was greatly
inhibited, suggesting that 2-AG-induced vasorelaxation is depend-
ent on K+ channel activation. This is a ﬁnding common with a
number of cannabinoid ligands in a range of vascular preparations
[58,59] including human arteries [60]. To determine a potential role
for calcium channels, some arteries were contracted using U46619
in calcium-free PSS, i.e. contraction dependent on release of calcium
from intracellular stores. Under these conditions, partial inhibition
of 2-AG-induced vasorelaxation was  observed. Cannabinoids also
cause vasorelaxation through inhibition of Ca2+ entry through volt-
age operated calcium channels [61]. In the present study, 2-AG, at
the highest concentrations, inhibited the maximum contraction to
calcium chloride. Taken together, these ﬁndings suggest that 2-AG
modulates ion channel activation to favour vasorelaxation, which
may  be coupled to prostanoid receptor activation or a direct action.
The magnitude of vasorelaxation varied between patient sam-
ples, therefore post hoc analysis was carried out to determine if
patient co-morbidities inﬂuenced the 2-AG response. These analy-
ses revealed that 2-AG pEC50 and Rmax responses were reduced in
patients with heart disease, type two  diabetes, those taking NSAID
medication and those taking anti-diabetic medication. It must be
noted that patient numbers used in this study were too small for
adequate statistical analysis of these ﬁndings. However based on
the ﬁndings of this study, future studies should investigate the
effects of disease and medication on the endocannabinoid system
in vascular function in humans.
5. Conclusion
We  have shown for the ﬁrst time that the endogenous cannabi-
noid 2-AG causes vasorelaxation of human mesenteric arteries.
This was  not mediated by CB1, CB2, TRPV1, the endothelium or
metabolism by FAAH or MAGL. Rather, vasorelaxation to 2-AG in
humans is dependent on COX-1 metabolism and subsequent activa-
tion of EP4 and IP prostanoid receptors. 2-AG responses vary greatly
between patients, which may  be related to underlying pathologies
or medication. Further work is required to fully understand the role
of 2-AG in human vasculature.
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